zoledronic acid
Selected indexed studies
- Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. (J Clin Oncol, 2001) [PMID:11208851]
- Zoledronic acid and fracture risk: a meta-analysis of 12 randomized controlled trials. (Eur Rev Med Pharmacol Sci, 2021) [PMID:33629326]
- Zoledronic acid. (Drugs, 2001) [PMID:11398911]
_Worker-drafted node — pending editorial review._
Connections
zoledronic acid is a side effect of
Sources
- Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. (2001) pubmed
- Zoledronic acid and fracture risk: a meta-analysis of 12 randomized controlled trials. (2021) pubmed
- Zoledronic acid. (2001) pubmed
- Zoledronic acid for the treatment of prostate cancer. (2019) pubmed
- Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma. (2018) pubmed
- Differences between zoledronic acid and denosumab for breast cancer treatment. (2023) pubmed
- Zoledronic acid-induced severe lymphopenia. (2023) pubmed
- Zoledronic Acid (Reclast(®), Aclasta(®)): A Review in Osteoporosis. (2016) pubmed
- Efficacy of zoledronic acid with percutaneous kyphoplasty/vertebroplasty in the treatment of osteoporotic vertebral compression fractures: a systematic review and meta-analysis. (2020) pubmed
- Zoledronic acid-induced orbital inflammation. (2021) pubmed